Firstly, all of the published studies strongly support the use of 18F-FDG PET in the clinical setting of BRAF-mutated MM submitted to targeted therapy, not only as a baseline examination for patients’ pre-therapeutic prognostic stratification but also for monitoring metabolic response to treatment. This evidence concerns the gene BRAF and Miyoshi myopathy.